HPV & head and neck cancer: a descriptive update.
HPV & head and neck cancer: a descriptive update.
复制标题
DOI：
10.1186/1758-3284-1-36
复制
发表时间：
2009-10-14
期刊：
影响因子：
--
通讯作者：
Sudhoff HH
中科院分区：
文献类型：
--
作者：
Goon PK;Stanley MA;Ebmeyer J;Steinsträsser L;Upile T;Jerjes W;Bernal-Sprekelsen M;Görner M;Sudhoff HH
头颈部鳞状细胞癌（HNSCC）的发病率在过去的三十年中逐渐增加。最近的数据现在已经将病毒病因归因于头颈癌的一个子集。几项研究表明，口腔人乳头瘤病毒（HPV）感染很可能是性获得性的。HPV 16在HPV+ HNSCC中的优势甚至大于在全世界总病例的宫颈癌中所见的优势。强有力的证据表明，HPV+状态是一个重要的预后因素，与头颈部癌症的良好结局相关。大约30 - 40%的HNSCC患者存在早期I/II期疾病。这些患者使用单一模式治疗（单独放射或手术）进行根治性治疗。对于手术后单纯放疗或放化疗可能导致严重功能损害的患者，非手术方法更受青睐。西妥昔单抗是一种人源化小鼠抗EGFR IgG 1单克隆抗体，与放疗联合治疗局部晚期肿瘤可改善局部控制和总生存率，但代价是心脏病发病率和死亡率增加。最后，HPV+肿瘤对化疗和放疗的预后和治疗反应的改善可能表明，需要进行HPV状态检测，以更好地规划和个性化患者治疗方案。
The incidence of head and neck squamous cell carcinoma (HNSCC) has been gradually increasing over the last three decades. Recent data have now attributed a viral aetiology to a subset of head and neck cancers. Several studies indicate that oral human papillomavirus (HPV) infection is likely to be sexually acquired. The dominance of HPV 16 in HPV+ HNSCC is even greater than that seen in cervical carcinoma of total worldwide cases. Strong evidence suggests that HPV+ status is an important prognostic factor associated with a favourable outcome in head and neck cancers. Approximately 30 to 40% of HNSCC patients with present with early stage I/II disease. These patients are treated with curative intent using single modality treatments either radiation or surgery alone. A non-operative approach is favored for patients in which surgery followed by either radiation alone or radiochemotherapy may lead to severe functional impairment. Cetuximab, a humanized mouse anti-EGFR IgG1 monoclonal antibody, improved locoregional control and overall survival in combination with radiotherapy in locally advanced tumours but at the cost of some increased cardiac morbidity and mortality. Finally, the improved prognosis and treatment responses to chemotherapy and radiotherapy by HPV+ tumours may suggest that HPV status detection is required to better plan and individualize patient treatment regimes.
登录
查看更多内容
DOI：
10.1016/j.ijrobp.2006.06.040
发表时间：
2006-11-15
影响因子：
7
作者：
Lee, Nancy Y.;de Arruda, Fernando F.;Zelefsky, Michael J.
通讯作者：
Zelefsky, Michael J.
影响因子：
158.5
作者：
Bernier, J;Domenge, C;van Glabbeke, M
通讯作者：
van Glabbeke, M
影响因子：
8.8
作者：
Chang, F;Syrjanen, S;Tervahauta, A;Kurvinen, K;Wang, L;Syrjanen, K
通讯作者：
Syrjanen, K
影响因子：
158.5
作者：
Bonner, JA;Harari, PM;Ang, KK
通讯作者：
Ang, KK
影响因子：
6.4
作者：
DONG, XP;STUBENRAUCH, F;PFISTER, H
通讯作者：
PFISTER, H